The Dynamics of Signaling as a Pharmacological Target

Highly networked signaling hubs are often associated with disease, but targeting them pharmacologically has largely been unsuccessful in the clinic because of their functional pleiotropy. Motivated by the hypothesis that a dynamic signaling code confers functional specificity, we investigated whether dynamic features may be targeted pharmacologically to achieve therapeutic specificity. With a virtual screen, we identified combinations of signaling hub topologies and dynamic signal profiles that are amenable to selective inhibition. Mathematical analysis revealed principles that may guide stimulus-specific inhibition of signaling hubs, even in the absence of detailed mathematical models. Using the NFκB signaling module as a test bed, we identified perturbations that selectively affect the response to cytokines or pathogen components. Together, our results demonstrate that the dynamics of signaling may serve as a pharmacological target, and we reveal principles that delineate the opportunities and constraints of developing stimulus-specific therapeutic agents aimed at pleiotropic signaling hubs.

[1]  Alexander Hoffmann,et al.  Understanding the temporal codes of intra-cellular signals. , 2010, Current opinion in genetics & development.

[2]  L. Bardwell,et al.  Mechanisms of MAPK signalling specificity. , 2006, Biochemical Society transactions.

[3]  M. Skwarczynska,et al.  Protein-protein interactions as drug targets. , 2015, Future medicinal chemistry.

[4]  Qing Nie,et al.  Ultrasensitive Responses and Specificity in Cell Signaling , 2010, BMC Systems Biology.

[5]  H. Kitano,et al.  A comprehensive map of the toll-like receptor signaling network , 2006, Molecular systems biology.

[6]  Richard Simon,et al.  In silico simulation of inhibitor drug effects on nuclear factor-kappaB pathway dynamics. , 2004, Molecular Pharmacology.

[7]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[8]  Wendell A. Lim,et al.  Conformational Control of the Ste5 Scaffold Protein Insulates Against MAP Kinase Misactivation , 2012, Science.

[9]  T. Elston,et al.  Kinetic insulation as an effective mechanism for achieving pathway specificity in intracellular signaling networks , 2007, Proceedings of the National Academy of Sciences.

[10]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[11]  Shinya Kuroda,et al.  Temporal coding of insulin action through multiplexing of the AKT pathway. , 2012, Molecular cell.

[12]  A. Hoffmann,et al.  Tunable signal processing through a kinase control cycle: the IKK signaling node. , 2013, Biophysical journal.

[13]  V. Imbert,et al.  Targeting NF-κB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells , 2005 .

[14]  Sherry L. Jenkins,et al.  Network analysis of FDA approved drugs and their targets. , 2007, The Mount Sinai journal of medicine, New York.

[15]  Jeremy E. Purvis,et al.  p53 Dynamics Control Cell Fate , 2012, Science.

[16]  Ursula Klingmüller,et al.  Short-term information processing, long-term responses: Insights by mathematical modeling of signal transduction , 2012, BioEssays : news and reviews in molecular, cellular and developmental biology.

[17]  Seth I. Berger,et al.  Role of systems pharmacology in understanding drug adverse events , 2011, Wiley interdisciplinary reviews. Systems biology and medicine.

[18]  M. Karin.  The IκB kinase – a bridge between inflammation and cancer , 2008, Cell Research.

[19]  V. Imbert,et al.  Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. , 2005, Blood.

[20]  J. O’Shea,et al.  Selectivity and therapeutic inhibition of kinases: to be or not to be? , 2009, Nature Immunology.

[21]  S. Cook,et al.  The duration of ERK1/2 activity determines the activation of c-Fos and Fra-1 and the composition and quantitative transcriptional output of AP-1. , 2007, Cellular signalling.

[22]  M. Karin.  Inflammation and Cancer , 2008 .

[23]  Fredrik Barrenäs,et al.  Network properties of human disease genes with pleiotropic effects , 2010, BMC Systems Biology.

[24]  A. Hoffmann,et al.  Circuitry of nuclear factor kappaB signaling. , 2006, Immunological reviews.

[25]  S. Véronneau,et al.  Signal-Regulated Kinase Activation Mobilization and Extracellular Platelet-Activating Factor-Mediated Calcium Caveolae Facilitate but Are Not Essential for , 2009 .

[26]  T. Brummer,et al.  Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside. , 2012, Critical reviews in oncogenesis.

[27]  J. McNally,et al.  Dynamic Effect of Bortezomib on Nuclear Factor-κB Activity and Gene Expression in Tumor Cells , 2008, Molecular Pharmacology.

[28]  Xiufen Zou,et al.  A theoretical framework for specificity in cell signaling , 2005, Molecular systems biology.

[29]  Wendell A. Lim,et al.  Rewiring MAP Kinase Pathways Using Alternative Scaffold Assembly Mechanisms , 2003, Science.

[30]  Ursula Klingmüller,et al.  Receptor dynamics in signaling. , 2012, Advances in experimental medicine and biology.

[31]  G. Lahav,et al.  Encoding and Decoding Cellular Information through Signaling Dynamics , 2013, Cell.

[32]  Alexander Hoffmann,et al.  Stimulus Specificity of Gene Expression Programs Determined by Temporal Control of IKK Activity , 2005, Science.

[33]  A. Hoffmann,et al.  The I (cid:1) B –NF-(cid:1) B Signaling Module: Temporal Control and Selective Gene Activation , 2022 .

[34]  Timothy C Elston,et al.  Control of MAPK Specificity by Feedback Phosphorylation of Shared Adaptor Protein Ste50* , 2008, Journal of Biological Chemistry.

[35]  V. Polunovsky,et al.  Translational control of cell fate: From integration of environmental signals to breaching anticancer defense , 2012, Cell cycle.

[36]  C. Marshall,et al.  Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation , 1995, Cell.

[37]  Ariel Fernández,et al.  Turning promiscuous kinase inhibitors into safer drugs. , 2008, Trends in biotechnology.

[38]  R. Weinberg,et al.  The Biology of Cancer , 2006 .

[39]  A. Hoffmann,et al.  The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. , 2002, Science.

[40]  Ye Guang Chen,et al.  Dishevelled: The hub of Wnt signaling. , 2010, Cellular signalling.

[41]  K. N. Chandrika,et al.  Analysis of the human protein interactome and comparison with yeast, worm and fly interaction datasets , 2006, Nature Genetics.

[42]  A. Hoffmann,et al.  NEMO ensures signaling specificity of the pleiotropic IKKβ by directing its kinase activity toward IκBα. , 2012, Molecular cell.

[43]  Michael Karin,et al.  A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. , 2012, Gastroenterology.

[44]  Alexander Hoffmann,et al.  IκBε provides negative feedback to control NF-κB oscillations, signaling dynamics, and inflammatory gene expression , 2006 .

[45]  M. Karin,et al.  NF‐κB and the link between inflammation and cancer , 2012, Immunological reviews.

[46]  R. A. Etten,et al.  Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition , 2007, Nature Reviews Cancer.

[47]  Alexander Hoffmann,et al.  IκBɛ provides negative feedback to control NF-κB oscillations, signaling dynamics, and inflammatory gene expression , 2006, The Journal of cell biology.